0001104659-26-087815 | 10-Q | XBRL Viewer

Print Document

Share-based compensation - PSU activity (Details) - Performance Share Units - 2014 Plan	6 Months Ended
	Jun. 30, 2026 $ / shares shares
Number of shares
Non-vested at beginning of period (in shares) \| shares	22,500
Granted (in shares) \| shares	28,750
Forfeited (in shares) \| shares	(22,500)
Non-vested at end of period (in shares) \| shares	28,750
Weighted average grant-date fair value
Non-vested at beginning of period (in dollars per share) \| $ / shares	$ 15.4
Granted (in dollars per share) \| $ / shares	22.4
Forfeited (in dollars per share) \| $ / shares	15.4
Non-vested at end of period (in dollars per share) \| $ / shares	$ 22.4

Current investment securities

6 Months Ended

Jun. 30, 2026

Current investment securities

Current investment securities

3	Current investment securities

The following tables summarize the Company’s investments in government debt securities as of June 30, 2026 and December 31, 2025:


		June 30, 2026
		Amortized cost			Gross unrealized holding gains			Gross unrealized holding losses			Estimated fair value

		(in thousands)
Current investments securities:
Government debt securities (held-to-maturity)		$	397,308		$	30		$	—		$	397,338
Total		$	397,308		$	30		$	—		$	397,338

		December 31, 2025
		Amortized cost			Gross unrealized holding gains			Gross unrealized holding losses			Estimated fair value

		(in thousands)
Current investments securities:
Government debt securities (held-to-maturity)		$	542,301		$	308		$	—		$	542,609
Total		$	542,301		$	308		$	—		$	542,609

The Company invests in short-term U.S. and European government debt securities with high investment credit ratings. The U.S. and European government bonds are U.S. dollar and euro (€, or EUR) denominated, respectively. Investment securities with original maturities of 90 days or less when purchased are presented within cash and cash equivalents and measured at amortized cost. Inputs to the fair value of the investments are considered Level 2 inputs.

As of June 30, 2026 and December 31, 2025, no expected credit loss was identified with respect to the investment securities.

Summary of significant accounting policies	6 Months Ended
Jun. 30, 2026
Summary of significant accounting policies
Summary of significant accounting policies	2Summary of significant accounting policies 2.1Basis of preparation The Company prepared these unaudited consolidated financial statements in compliance with generally accepted accounting principles in the United States (“U.S. GAAP”) and applicable rules and regulations of the United States Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Any reference in these notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates of the Financial Accounting Standards Board. The unaudited consolidated financial statements are presented in United States (“U.S.”) dollars, except where otherwise indicated. Transactions denominated in currencies other than U.S. dollars are presented in the transaction currency with the U.S. dollar amount included in parentheses, converted at the foreign exchange rate as of the transaction date. 2.2Unaudited interim financial information The interim financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the financial position, results of operations and changes in financial position for the period presented. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been omitted. The results of operations for the three and six months ended June 30, 2026, are not necessarily indicative of the results to be expected for the full year ending December 31, 2026, or for any other future year or interim period. The accompanying financial statements should be read in conjunction with the audited financial statements and the related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed by the Company with the SEC on March 2, 2026 (the “Annual Report”). 2.3Use of estimates The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities; the disclosure of contingent liabilities at the date of the financial statements; and the reported amounts of revenues, expenses, and tax-related items during the reporting period. Actual results could differ from those estimates. 2.4Accounting policies The principal accounting policies applied in the preparation of these unaudited consolidated financial statements are described in the Company’s audited financial statements as of and for the year ended December 31, 2025, and the notes thereto, which are included in the Annual Report. There have been no material changes in the Company’s significant accounting policies during the six months ended June 30, 2026. 2.5Recent accounting pronouncements There have been no new accounting pronouncements or changes to accounting pronouncements during the six months ended June 30, 2026, as compared to the recent accounting pronouncements described in Note 2.3.29 of the Annual Report, which could be expected to materially impact the Company’s unaudited consolidated financial statements.

Summary of significant accounting policies

6 Months Ended

Jun. 30, 2026

Summary of significant accounting policies

Summary of significant accounting policies

2Summary of significant accounting policies

2.1Basis of preparation

The Company prepared these unaudited consolidated financial statements in compliance with generally accepted accounting principles in the United States (“U.S. GAAP”) and applicable rules and regulations of the United States Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Any reference in these notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates of the Financial Accounting Standards Board.

The unaudited consolidated financial statements are presented in United States (“U.S.”) dollars, except where otherwise indicated. Transactions denominated in currencies other than U.S. dollars are presented in the transaction currency with the U.S. dollar amount included in parentheses, converted at the foreign exchange rate as of the transaction date.

2.2Unaudited interim financial information

The interim financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the financial position, results of operations and changes in financial position for the period presented.

Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been omitted. The results of operations for the three and six months ended June 30, 2026, are not necessarily indicative of the results to be expected for the full year ending December 31, 2026, or for any other future year or interim period. The accompanying financial statements should be read in conjunction with the audited financial statements and the related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed by the Company with the SEC on March 2, 2026 (the “Annual Report”).

2.3Use of estimates

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities; the disclosure of contingent liabilities at the date of the financial statements; and the reported amounts of revenues, expenses, and tax-related items during the reporting period. Actual results could differ from those estimates.

2.4Accounting policies

The principal accounting policies applied in the preparation of these unaudited consolidated financial statements are described in the Company’s audited financial statements as of and for the year ended December 31, 2025, and the notes thereto, which are included in the Annual Report. There have been no material changes in the Company’s significant accounting policies during the six months ended June 30, 2026.

2.5Recent accounting pronouncements

There have been no new accounting pronouncements or changes to accounting pronouncements during the six months ended June 30, 2026, as compared to the recent accounting pronouncements described in Note 2.3.29 of the Annual Report, which could be expected to materially impact the Company’s unaudited consolidated financial statements.

Segment reporting - Schedule of segment reporting (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2026 USD ($) segment	Jun. 30, 2025 USD ($)
Segment reporting
Number of operating segments \| segment			1
Number of reportable segments \| segment			1
Loss from operations	$ (52,203)	$ (43,865)	$ (97,923)	$ (83,196)
Depreciation and amortization expense			(7,863)	(8,157)
Fair value (loss) / gain - contingent consideration			82	(3,470)
Fair value loss - Liability related to pre-funded warrants			12,201
Foreign currency (losses) / gains, net	(1,730)	18,638	(4,024)	25,810
Interest income	5,051	3,524	10,280	7,651
Interest expense - Royalty Financing Agreement			(17,384)	(20,626)
Other reconciling items	(15,970)		(12,201)
Loss before income tax expense	(79,218)	(37,294)	(132,265)	(80,435)
Operating Segment \| Single Reportable Segment
Segment reporting
Revenue	5,841	5,262	9,403	6,829
Employee related expenses	(16,960)	(14,525)	(33,746)	(28,741)
Laboratory and development expenses	(17,387)	(15,593)	(32,148)	(31,560)
Professional fees	(1,756)	(3,124)	(6,263)	(5,181)
Information technology system costs	(1,427)	(838)	(3,086)	(1,839)
Facility expenses	(1,437)	(1,704)	(2,984)	(3,371)
Other segment items(1)	(2,511)	(1,804)	(6,024)	(2,773)
Loss from operations	$ (35,637)	$ (32,326)	$ (74,848)	$ (66,636)
Other segment items description	(1) Other segment items included in segment operating loss include costs related to intellectual property and insurance offset by income related to payments received from European authorities to subsidize the Company's research and development in the Netherlands. (2) The comparative amounts for the three and six months ended June 30, 2025 have been adjusted to reflect the level of detail at which the CODM reviews segment operating expenses in 2026, with information technology system costs presented as a separate line item and consumables included within other segment items for all periods presented.	(1) Other segment items included in segment operating loss include costs related to intellectual property and insurance offset by income related to payments received from European authorities to subsidize the Company's research and development in the Netherlands. (2) The comparative amounts for the three and six months ended June 30, 2025 have been adjusted to reflect the level of detail at which the CODM reviews segment operating expenses in 2026, with information technology system costs presented as a separate line item and consumables included within other segment items for all periods presented.	(1) Other segment items included in segment operating loss include costs related to intellectual property and insurance offset by income related to payments received from European authorities to subsidize the Company's research and development in the Netherlands. (2) The comparative amounts for the three and six months ended June 30, 2025 have been adjusted to reflect the level of detail at which the CODM reviews segment operating expenses in 2026, with information technology system costs presented as a separate line item and consumables included within other segment items for all periods presented.	(1) Other segment items included in segment operating loss include costs related to intellectual property and insurance offset by income related to payments received from European authorities to subsidize the Company's research and development in the Netherlands. (2) The comparative amounts for the three and six months ended June 30, 2025 have been adjusted to reflect the level of detail at which the CODM reviews segment operating expenses in 2026, with information technology system costs presented as a separate line item and consumables included within other segment items for all periods presented.
Material Reconciling \| Single Reportable Segment
Segment reporting
Depreciation and amortization expense	$ (4,907)	$ (3,630)	$ (7,863)	$ (8,157)
Share-based compensation expense	(5,016)	(5,084)	(10,106)	(9,494)
Fair value (loss) / gain - contingent consideration	(1,256)	(2,254)	82	(3,470)
Fair value loss - Liability related to pre-funded warrants	(15,970)		(12,201)
Foreign currency (losses) / gains, net	(1,730)	18,638	(4,024)	25,810
Interest income	5,051	3,524	10,280	7,651
Interest expense - Royalty Financing Agreement	(12,963)	(13,770)	(25,584)	(27,079)
Interest expense - Hercules debt facility	(1,403)	(1,821)	(2,813)	(3,621)
Other reconciling items	$ (5,387)	$ (571)	$ (5,188)	$ 4,561

Shareholders' equity

6 Months Ended

Jun. 30, 2026

Shareholders' equity

Shareholders' equity

8Shareholders’ equity

In June 2026, the Company received net proceeds of $242.7 million, after deducting underwriting discounts and commissions and other offering expenses payable by the Company, through a follow-on public offering of 5.7 million ordinary shares, at a public offering price of $45.50 per ordinary share.

In June 2026, the Company's shareholders approved an amendment to the Articles of Association increasing the Company's authorized share capital from 80.0 million ordinary shares to 100.0 million ordinary shares with a nominal value of €0.05 per share.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

Current investment securities (Tables)

6 Months Ended

Jun. 30, 2026

Current investment securities

Schedule of investments in government debt securities


		June 30, 2026
		Amortized cost			Gross unrealized holding gains			Gross unrealized holding losses			Estimated fair value

		(in thousands)
Current investments securities:
Government debt securities (held-to-maturity)		$	397,308		$	30		$	—		$	397,338
Total		$	397,308		$	30		$	—		$	397,338

		December 31, 2025
		Amortized cost			Gross unrealized holding gains			Gross unrealized holding losses			Estimated fair value

		(in thousands)
Current investments securities:
Government debt securities (held-to-maturity)		$	542,301		$	308		$	—		$	542,609
Total		$	542,301		$	308		$	—		$	542,609

- Definition

Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (aaa)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A

Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B

Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B

Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B

+ Details

Segment reporting (Tables)

6 Months Ended

Jun. 30, 2026

Segment reporting

Schedule of segment reporting


		Three months ended June 30,					Six months ended June 30,
		2026			2025		2026			2025

		(in thousands)					(in thousands)
Revenue		$	5,841		$	5,262	$	9,403		$	6,829
Less:
Employee related expenses			(16,960)			(14,525)		(33,746)			(28,741)
Laboratory and development expenses			(17,387)			(15,593)		(32,148)			(31,560)
Professional fees			(1,756)			(3,124)		(6,263)			(5,181)
Information technology system costs⁽²⁾			(1,427)			(838)		(3,086)			(1,839)
Facility expenses			(1,437)			(1,704)		(2,984)			(3,371)
Other segment items^{(1) (2)}			(2,511)			(1,804)		(6,024)			(2,773)
Segment operating loss			(35,637)			(32,326)		(74,848)			(66,636)
Reconciliation
Depreciation and amortization expense			(4,907)			(3,630)		(7,863)			(8,157)
Share-based compensation expense			(5,016)			(5,084)		(10,106)			(9,494)
Fair value (loss) / gain - contingent consideration			(1,256)			(2,254)		82			(3,470)
Fair value loss - Liability related to pre-funded warrants			(15,970)			—		(12,201)			—
Foreign currency (losses) / gains, net			(1,730)			18,638		(4,024)			25,810
Interest income			5,051			3,524		10,280			7,651
Interest expense - Royalty Financing Agreement			(12,963)			(13,770)		(25,584)			(27,079)
Interest expense - Hercules loan facility			(1,403)			(1,821)		(2,813)			(3,621)
Other reconciling items			(5,387)			(571)		(5,188)			4,561
Consolidated loss before income tax expense		$	(79,218)		$	(37,294)	$	(132,265)		$	(80,435)

(1)

Other segment items included in segment operating loss include costs related to intellectual property and insurance offset by income related to payments received from European authorities to subsidize the Company’s research and development in the Netherlands.

(2)

The comparative amounts for the three and six months ended June 30, 2025 have been adjusted to reflect the level of detail at which the CODM reviews segment operating expenses in 2026, with information technology system costs presented as a separate line item and consumables included within other segment items for all periods presented.

Shareholders' equity (Details) $ / shares in Units, $ in Thousands	1 Months Ended	6 Months Ended
	Jun. 30, 2026 USD ($) $ / shares shares	Jun. 30, 2026 USD ($) $ / shares shares	Jun. 30, 2025 USD ($)	Jun. 30, 2026 € / shares shares	May 31, 2026 shares	Dec. 31, 2025 € / shares shares
Shareholders' equity
Net proceeds \| $	$ 242,700	$ 242,681	$ 80,511
Offering expenses payable through public offering	5,700,000
Offering price per share of shares issued \| $ / shares	$ 45.5	$ 45.5
Shares authorized	100,000,000	100,000,000		100,000,000	80,000,000	80,000,000
Ordinary shares, par value (in euros per share) \| € / shares				€ 0.05		€ 0.05

Fair value measurement - Contingent Consideration (Details) $ in Thousands, € in Millions	6 Months Ended			12 Months Ended
	Jun. 30, 2026 USD ($)	Jun. 30, 2026 EUR (€)	Jun. 30, 2025 USD ($)	Dec. 31, 2025 USD ($)	Jun. 30, 2026 EUR (€)	Dec. 31, 2025 EUR (€)
Fair value measurement
Contingent consideration	$ 18,113			$ 18,736
Changes in fair value of contingent consideration	$ (82)		$ 3,470
One hundred percent likelihood of AMT-260 advancing into clinical development
Fair value measurement
Percentage of increase in Probability of Success	100.00%	100.00%
Changes in fair value of contingent consideration	$ 58,400	€ 51.3
uniQure France [S.A.S]
Fair value measurement
Contingent consideration	18,113			$ 18,736	€ 15.9	€ 15.9
Contingent consideration discount rate percentage				11.80%
Changes in fair value of contingent consideration	(82)
uniQure France [S.A.S] \| Maximum
Fair value measurement
Contingent consideration payable upon achievement of contractually defined milestones	$ 163,000				€ 143.1
Contingent consideration discount rate percentage	11.80%	11.80%
uniQure France [S.A.S] \| Minimum
Fair value measurement
Contingent consideration discount rate percentage	10.10%	10.10%

Long-term debt (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
Long-term debt (Details) - USD ($) $ in Millions	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Jul. 31, 2026	Dec. 31, 2025
2025 Amended Facility
Long-term debt
Maximum borrowing capacity	$ 50.0		$ 50.0
Line of credit	50.5		50.5			$ 50.1
Foreign currency loss	0.5		1.6
Foreign currency gain		$ 4.3		$ 6.4
Interest expense recorded	$ 1.4	$ 1.8	$ 2.8	$ 3.6
2026 Amended Facility \| Tranche Based on Approval of AMT-130 \| Subsequent event
Long-term debt
Maximum borrowing capacity					$ 100.0

Fair value measurement - Liability related to pre-funded warrants (Details) - Pre-Funded Warrants	Sep. 30, 2025 $ / shares shares
Class of Warrant or Right
Warrants to purchase shares \| shares	526,316
Public offering price	$ 47.5
Warrants exercise price	$ 0.0001

Fair value measurement - Changes in fair value of contingent consideration (Details) $ in Thousands, € in Millions	6 Months Ended
	Jun. 30, 2026 USD ($)	Jun. 30, 2026 EUR (€)	Jun. 30, 2025 USD ($)
Fair value measurement
Beginning Balance	$ 18,736
Unrealized change in fair value (presented within Research and development expenses)	(82)		$ 3,470
Ending Balance	18,113
uniQure France [S.A.S]
Fair value measurement
Beginning Balance	18,736	€ 15.9
Unrealized change in fair value (presented within Research and development expenses)	(82)
Currency translation effects	(541)
Ending Balance	$ 18,113	€ 15.9

Fair value measurement

6 Months Ended

Jun. 30, 2026

Fair value measurement.

Fair value measurement

4	Fair value measurement

The Company measures certain financial assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. ASC 820, Fair Value Measurement requires disclosure of the methodologies used in determining the reported fair values and establishes a hierarchy of inputs used when available. The three levels of the fair value hierarchy are described below:

Level 1 – Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company can access at the measurement date.

Level 2 – Valuations based on quoted prices for similar assets or liabilities in markets that are not active or models for which the inputs are observable, either directly or indirectly.

Level 3 – Valuations that require inputs that reflect the Company’s own assumptions that are both significant to the fair value measurement and are unobservable.

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The carrying amount of cash and cash equivalents, accounts receivable from licensing and collaboration partners, other assets, accounts payable, accrued expenses and other current liabilities reflected in the Unaudited Consolidated Balance Sheets approximate their fair values due to their short-term maturities.

The Company’s material financial assets include cash and cash equivalents, restricted cash and investment securities. Cash and cash equivalents and restricted cash are measured at fair value using Level 1 inputs. Restricted cash is included in Other non-current assets within the Unaudited Consolidated Balance Sheets. Investment securities are measured at amortized cost.

The following table sets forth the Company’s assets and liabilities that are required to be measured at fair value on a recurring basis as of June 30, 2026 and December 31, 2025:


		Quoted prices in active markets (Level 1)			Significant other observable inputs (Level 2)			Significant unobservable inputs (Level 3)			Total			Classification in Unaudited Consolidated Balance Sheets

			(in thousands)
Balance at December 31, 2025
Assets:
Cash and cash equivalents		$	80,240		$	—		$	—		$	80,240		Cash and cash equivalents
Restricted cash			1,561			—			—			1,561		Other non-current assets
Total assets		$	81,801		$	—		$	—		$	81,801
Liabilities:
Liability related to pre-funded warrants			—			12,595			—			12,595		Liability related to pre-funded warrants
Contingent consideration			—			—			18,736			18,736		Contingent consideration
Consideration for post-acquisition services			—			—			638			638		Other non-current liabilities
Total liabilities		$	—		$	12,595		$	19,374		$	31,969
Balance at June 30, 2026
Assets:
Cash and cash equivalents		$	413,027		$	—		$	—		$	413,027		Cash and cash equivalents
Restricted cash			1,534			—			—			1,534		Other non-current assets
Total assets		$	414,561		$	—		$	—		$	414,561
Liabilities:
Liability related to pre-funded warrants			—			24,242			—			24,242		Liability related to pre-funded warrants
Contingent consideration			—			—			18,113			18,113		Contingent consideration
Consideration for post-acquisition services			—			—			617			617		Other non-current liabilities
Total liabilities		$	—		$	24,242		$	18,730		$	42,972

Contingent consideration

The Company is required to pay up to EUR 143.1 million (or $163.0 million based on the foreign exchange rate on June 30, 2026) to the former shareholders of uniQure France SAS (formerly Corlieve Therapeutics SAS) upon the achievement of the remaining contractually defined milestones related to the development of AMT-260 in connection with the Company’s acquisition of uniQure France SAS.

The fair value of the contingent consideration as of June 30, 2026 was EUR 15.9 million ($18.1 million) (December 31, 2025: EUR 15.9 million ($18.7 million)) using discount rates of approximately 10.1% to 11.8% (December 31, 2025: 11.8%).

If, as of June 30, 2026, the Company had assumed a 100% likelihood of AMT-260 advancing into a Phase III clinical study, then the fair value of the contingent consideration would have increased to EUR 51.3 million ($58.4 million). If, as of June 30, 2026, the Company had assumed that it would discontinue development of the AMT-260 program, then the contingent consideration would have been released to income.

The following table presents the changes in fair value of the contingent consideration (presented within non-current liabilities) between December 31, 2025 and June 30, 2026:


	Amount of
	contingent
	consideration
	(in thousands)
Balance at December 31, 2025	$	18,736
Unrealized change in fair value (presented within Research and development expenses)		(82)
Currency translation effects		(541)
Balance at June 30, 2026	$	18,113

The Company classified the total contingent consideration liability as non-current as of June 30, 2026 and December 31, 2025. The classification of the contingent consideration within the Company’s Unaudited Consolidated Balance Sheets between current and non-current liabilities is based upon the Company’s best estimate of the timing of settlement of the remaining relevant milestones.

Liability related to pre-funded warrants

In September 2025, the Company completed a follow-on public offering which included the issuance of pre-funded warrants to purchase 526,316 of the Company’s ordinary shares at the public offering price of $47.50 per ordinary share, less a $0.0001 per ordinary share exercise price for each pre-funded warrant (“Pre-Funded Warrant(s)”). The obligation to issue ordinary shares upon the exercise of the Pre-Funded Warrants is classified as a liability related to pre-funded warrants.

The Pre-Funded Warrants are not exchange-quoted and are measured using a valuation technique whose significant inputs are observable; therefore, the fair value measurement is classified within Level 2 of the fair value hierarchy.


	Liability related
	to pre-funded
	warrants
	(in thousands)
Balance at December 31, 2025	$	12,595
Unrealized increase in fair value (presented within Other non-operating (losses), net)		12,201
Currency translation effects		(554)
Balance at June 30, 2026	$	24,242

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

+ Details

Basic and diluted loss per share (Tables)

6 Months Ended

Jun. 30, 2026

Basic and diluted loss per share

Schedule of potentially dilutive ordinary shares


	Three months ended June 30,						Six months ended June 30,
	2026			2025			2026			2025
Anti-dilutive ordinary share equivalents
Stock options under 2014 Plans	$	4,962,265		$	5,321,862		$	4,962,265		$	5,321,862
Non-vested RSUs and PSUs		2,536,549			2,442,969			2,536,549			2,442,969
Pre-Funded Warrants		526,316			—			526,316			—
ESPP		13,939			—			13,939			—
Total anti-dilutive ordinary share equivalents		8,039,069			7,764,831			8,039,069			7,764,831

Royalty Financing Agreement - Movement in the liability (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
Income taxes paid
Beginning balance			$ 473,199
Interest expense for the period			17,384	$ 20,626
Ending balance	$ 489,333		489,333
Liability owed to the Purchaser (presented as "Accrued expense and other current liabilities")	5,778		5,778		$ 5,523
Royalty Financing Agreement
Income taxes paid
Beginning balance			478,722
Royalty payments to the Purchaser			(9,195)
Interest expense for the period	13,000	$ 13,800	25,584	$ 27,100
Ending balance	495,111		495,111
Liability owed to the Purchaser (presented as "Accrued expense and other current liabilities")	$ 5,800		$ 5,800		$ 5,500

Share-based compensation - RSU activity (Details) - Restricted Share Units - 2014 Plan $ / shares in Units, $ in Millions	6 Months Ended
	Jun. 30, 2026 USD ($) $ / shares shares
Number of shares
Non-vested at beginning of period (in shares) \| shares	2,395,420
Granted (in shares) \| shares	1,112,250
Vested (in shares) \| shares	(886,521)
Forfeited (in shares) \| shares	(113,350)
Non-vested at end of period (in shares) \| shares	2,507,799
Weighted average grant-date fair value
Non-vested at beginning of period (in dollars per share) \| $ / shares	$ 12.15
Granted (in dollars per share) \| $ / shares	12.36
Vested (in dollars per share) \| $ / shares	12.29
Forfeited (in dollars per share) \| $ / shares	16.22
Non-vested at end of period (in dollars per share) \| $ / shares	$ 12.01
Other disclosure
Total weighted average grant date fair value of RSUs granted during the period (in millions) \| $	$ 13.8
Non-Executive Directors
Other disclosure
Vesting period (in years)	1 year
Maximum \| Other than non-executive directors
Other disclosure
Vesting period (in years)	3 years

Share-based compensation (Tables)

6 Months Ended

Jun. 30, 2026

Share-based compensation

Schedule of share-based compensation expense by classification included in consolidated statements of operations and comprehensive loss

Three months ended June 30,

Six months ended June 30,

 

2026

 

2025

 

2026

 

2025

(in thousands)

Research and development expenses

1,888

2,758

3,865

5,221

Selling, general and administrative expenses

3,128

2,326

6,241

4,273

Total

5,016

5,084

10,106

9,494

Schedule of share-based compensation expense / (income)


		Three months ended June 30,						Six months ended June 30,
		2026			2025			2026			2025

		(in thousands)						(in thousands)
Award type/ESPP
Share options		$	1,861		$	1,662		$	3,668		$	3,299
Restricted share units			3,255			2,547			6,461			4,760
Performance share units			(108)			875			(46)			1,435
ESPP			8			—			23			—
Total		$	5,016		$	5,084		$	10,106		$	9,494

Schedule of unrecognized compensation expense related to unvested awards


	Unrecognized		Weighted average
	share-based		remaining
	compensation		period for
	expense		recognition
	(in thousands)		(in years)
Award type
Share options	$	14,464	2.57
Restricted share units		25,886	2.17
Performance share units		427	0.87
Total	$	40,776	2.30

Schedule of weighted-average assumptions for fair value of option issued


		Three months ended June 30,				Six months ended June 30,
		2026		2025		2026		2025
Assumptions
Expected volatility		95%		80%		95%		70% - 80%
Expected terms		10 years		10 years		10 years		10 years
Risk-free interest rate		4.68%		4.64%		4.21% - 4.68%		4.36% - 4.64%
Expected dividend yield		0.0%		0.0%		0.0%		0.0%

Summary of RSUs activity


	RSUs
		Weighted average
	Number of	grant-date fair
	ordinary shares	value
Non-vested at December 31, 2025	2,395,420	$	12.15
Granted	1,112,250	$	12.36
Vested	(886,521)	$	12.29
Forfeited	(113,350)	$	16.22
Non-vested at June 30, 2026	2,507,799	$	12.01

Total weighted average grant date fair value of RSUs granted during the period (in $ millions)		$	13.8

Summary of PSUs activity


	PSUs
		Weighted average
	Number of	grant-date fair
	ordinary shares	value
Non-vested at December 31, 2025	22,500	$	15.40
Granted	28,750	$	22.40
Vested	—	$	—
Forfeited	(22,500)	$	15.40
Non-vested at June 30, 2026	28,750	$	22.40

2014 Plan

Share-based compensation

Summary of option activity


	Options
	Number of ordinary shares			Weighted average exercise price

Outstanding at December 31, 2025	4,531,991			17.04
Granted	869,760		$	11.48
Forfeited	(12,451)		$	9.58
Expired	(16,186)		$	37.84
Exercised	(410,849)		$	16.60
Outstanding at June 30, 2026	4,962,265		$	16.05
Thereof, fully vested, and exercisable on June 30, 2026	2,769,675		$	19.77
Thereof, outstanding and expected to vest after June 30, 2026	2,192,590		$	11.35
Outstanding and expected to vest after December 31, 2025	1,999,315		$	11.81


Total weighted average grant date fair value of options issued during the period (in $ millions)				$	6.4

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Summary of significant accounting policies (Policies)	6 Months Ended
Summary of significant accounting policies (Policies)	Jun. 30, 2026
Summary of significant accounting policies
Basis of preparation	2.1Basis of preparation The Company prepared these unaudited consolidated financial statements in compliance with generally accepted accounting principles in the United States (“U.S. GAAP”) and applicable rules and regulations of the United States Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Any reference in these notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates of the Financial Accounting Standards Board. The unaudited consolidated financial statements are presented in United States (“U.S.”) dollars, except where otherwise indicated. Transactions denominated in currencies other than U.S. dollars are presented in the transaction currency with the U.S. dollar amount included in parentheses, converted at the foreign exchange rate as of the transaction date.
Unaudited interim financial information	2.2Unaudited interim financial information The interim financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the financial position, results of operations and changes in financial position for the period presented. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been omitted. The results of operations for the three and six months ended June 30, 2026, are not necessarily indicative of the results to be expected for the full year ending December 31, 2026, or for any other future year or interim period. The accompanying financial statements should be read in conjunction with the audited financial statements and the related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed by the Company with the SEC on March 2, 2026 (the “Annual Report”).
Use of estimates	2.3Use of estimates The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities; the disclosure of contingent liabilities at the date of the financial statements; and the reported amounts of revenues, expenses, and tax-related items during the reporting period. Actual results could differ from those estimates.
Accounting policies	2.4Accounting policies The principal accounting policies applied in the preparation of these unaudited consolidated financial statements are described in the Company’s audited financial statements as of and for the year ended December 31, 2025, and the notes thereto, which are included in the Annual Report. There have been no material changes in the Company’s significant accounting policies during the six months ended June 30, 2026.
Recent accounting pronouncements	2.5Recent accounting pronouncements There have been no new accounting pronouncements or changes to accounting pronouncements during the six months ended June 30, 2026, as compared to the recent accounting pronouncements described in Note 2.3.29 of the Annual Report, which could be expected to materially impact the Company’s unaudited consolidated financial statements.

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-12

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-9

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482836/275-10-55-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-4

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-SubTopic 10
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-SubTopic 10
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1

+ Details

Accrued expenses and other current liabilities (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2026	Dec. 31, 2025
Accrued expenses and other current liabilities
Accruals for goods received from and services provided by vendors, not yet billed	$ 24,684	$ 20,490
Personnel-related accruals and liabilities (As of June 30, 2026, $7.2 million (December 31, 2025: $0.0 million) related to cash proceeds from employees' stock option exercises)	16,654	9,941
Liability owed to the Purchaser pursuant to the Royalty Financing Agreement (refer to Note 7, "Royalty Financing Agreement")	5,778	5,523
Current portion of firm purchase commitment liability (including Genezen CSA termination payment)	3,808	5,102
Other current liabilities	209	236
Total	51,133	41,292
Cash proceeds from employees' stock option exercises	$ 7,200	$ 0

Other investments and concentration of credit risk - Additional Information (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025	Jun. 30, 2025
Concentration Risk [Line Items]
Convertible note receivable	$ 15,124	$ 14,622
Accounts receivable	5,778	5,863
Genezen
Concentration Risk [Line Items]
Prepayments	5,700	13,900
Convertible note receivable	15,100	14,600
Expected credit losses	0		$ 0
CSL Behring
Concentration Risk [Line Items]
Accounts receivable	$ 5,800	$ 5,900

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-18

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-18

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-20

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-18

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-18

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-18

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482836/275-10-55-18

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-20

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 954
-SubTopic 310
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478785/954-310-50-2

+ Details

Other investments and concentration of credit risk

6 Months Ended

Jun. 30, 2026

Other investments and concentration of credit risk

Other investments and concentration of credit risk

11	Other investments and concentration of credit risk

The following table summarizes the Company’s other investments as of June 30, 2026 and December 31, 2025:


		June 30,			December 31,
		2026			2025

		(in thousands)
Carrying amount of equity investments		$	15,143		$	15,615
Convertible note receivable			15,124			14,622
Total		$	30,267		$	30,237

The Company holds investments in non-publicly traded equity securities without readily determinable fair values. These investments are accounted for at cost, less impairment and adjusted to fair value if there are observable price changes in orderly transactions for identical or similar investments using the measurement alternative in accordance with ASC 321, Investments – Equity Securities. The carrying value of these investments as of June 30, 2026 and December 31, 2025 was $15.1 million and $15.6 million, respectively, and are presented within Other Investments in the Company’s Consolidated Balance Sheets.

The Company did not recognize any upward adjustments, downward adjustments, or impairments relating to investments carried under the measurement alternative during the three and six months ended June 30, 2026, and 2025.

Genezen

In 2024, as part of the Company’s divestment of its commercial manufacturing operations to Genezen, the Company entered into various service agreements including the Genezen CSA. In April 2026, the Company entered into an agreement to terminate the Genezen CSA. Pursuant to the termination agreement, the Company’s obligation to supply HEMGENIX^® and any minimum purchase commitments under the Genezen CSA terminate once contractually specified batches have been supplied.

The Company’s prepayments for services to be received amounted to $5.7 million as of June 30, 2026, compared to $13.9 million as of December 31, 2025. In addition, as of June 30, 2026, the Company holds a convertible note receivable of $15.1 million which is due in September 2029 and for which Genezen is the counterparty (December 31, 2025: $14.6 million).

These balances represent a concentration of credit risk, and the Company’s maximum exposure to loss is the carrying value of these assets. No expected credit losses were recognized during the three and six months ended June 30, 2026 or 2025.

CSL Behring

As of June 30, 2026 and December 31, 2025, accounts receivable from CSL Behring LLC (“CSL Behring”) totaled $5.8 million and $5.9 million, respectively, in each case related to royalty revenue which is included in License Revenue in the accompanying statements of operations and comprehensive loss.

Share-based compensation - Summary of share-based compensation expense and unrecognized costs (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2018	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
2014 Plan
Share-based compensation
Increase in authorized shares	350,000
Ordinary shares available for issue	2,815,628		2,815,628		2,815,628
Unrecognized compensation costs	$ 40,776		$ 40,776		$ 40,776
Weighted-average remaining period for recognition (in years)					2 years 3 months 18 days
2014 Plans and ESPP
Share-based compensation
Share-based compensation expense			5,016	$ 5,084	$ 10,106	$ 9,494
Research and development expenses \| 2014 Plans and ESPP
Share-based compensation
Share-based compensation expense			1,888	2,758	3,865	5,221
Selling, general and administrative expenses \| 2014 Plans and ESPP
Share-based compensation
Share-based compensation expense			3,128	2,326	6,241	4,273
Share options \| 2014 Plan
Share-based compensation
Unrecognized compensation costs	14,464		14,464		$ 14,464
Weighted-average remaining period for recognition (in years)					2 years 6 months 25 days
Share options \| 2014 Plans and ESPP
Share-based compensation
Share-based compensation expense			1,861	1,662	$ 3,668	3,299
Restricted Share Units \| 2014 Plan
Share-based compensation
Unrecognized compensation costs	25,886		25,886		$ 25,886
Weighted-average remaining period for recognition (in years)					2 years 2 months 1 day
Restricted Share Units \| 2014 Plans and ESPP
Share-based compensation
Share-based compensation expense			3,255	2,547	$ 6,461	4,760
Performance Share Units \| 2014 Plan
Share-based compensation
Unrecognized compensation costs	$ 427		427		$ 427
Weighted-average remaining period for recognition (in years)					10 months 13 days
Performance Share Units \| 2014 Plans and ESPP
Share-based compensation
Share-based compensation expense			$ (108)	$ 875	$ (46)	$ 1,435
ESPP \| Employee Share Purchase Plan
Share-based compensation
Ordinary shares available for issue	72,773	150,000	72,773	86,712	72,773	86,712
Discounted rate for purchase of shares		85.00%
Issuance of ordinary shares relating to employee stock purchase plan (in shares)					13,939	0
ESPP \| 2014 Plans and ESPP
Share-based compensation
Share-based compensation expense			$ 8		$ 23

Basic and diluted loss per share - Anti-dilutive ordinary shares (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Basic and diluted loss per share
Total anti-dilutive ordinary share equivalents	8,039,069	7,764,831	8,039,069	7,764,831
ESPP
Basic and diluted loss per share
Total anti-dilutive ordinary share equivalents	13,939		13,939
Stock options under 2014 Plans
Basic and diluted loss per share
Total anti-dilutive ordinary share equivalents	4,962,265	5,321,862	4,962,265	5,321,862
Non-vested RSUs and PSUs
Basic and diluted loss per share
Total anti-dilutive ordinary share equivalents	2,536,549	2,442,969	2,536,549	2,442,969
Pre-Funded Warrants
Basic and diluted loss per share
Total anti-dilutive ordinary share equivalents	526,316		526,316

Segment reporting

6 Months Ended

Jun. 30, 2026

Segment reporting

Segment reporting

10	Segment reporting

The Company is advancing a pipeline of innovative gene therapies seeking to deliver to patients suffering from rare and other devastating diseases single treatments with potentially curative results. The Company manages the operations related to these research and development activities within one operating segment because they rely on a common set of infrastructure, resources and technology of the products and production processes, types of customers, distribution methods and regulatory environment.

The leadership team is identified as the Chief Operating Decision Maker (“CODM”).

The CODM allocates resources to research projects and clinical candidates based on scientific data as well as quantitative and qualitative expected risk-adjusted returns on investment. The CODM uses segment operating loss to monitor that cash operating losses remain within the approved budget.

The accounting policies of the operating segment are the same as those described in the summary of significant accounting policies.


		Three months ended June 30,					Six months ended June 30,
		2026			2025		2026			2025

		(in thousands)					(in thousands)
Revenue		$	5,841		$	5,262	$	9,403		$	6,829
Less:
Employee related expenses			(16,960)			(14,525)		(33,746)			(28,741)
Laboratory and development expenses			(17,387)			(15,593)		(32,148)			(31,560)
Professional fees			(1,756)			(3,124)		(6,263)			(5,181)
Information technology system costs⁽²⁾			(1,427)			(838)		(3,086)			(1,839)
Facility expenses			(1,437)			(1,704)		(2,984)			(3,371)
Other segment items^{(1) (2)}			(2,511)			(1,804)		(6,024)			(2,773)
Segment operating loss			(35,637)			(32,326)		(74,848)			(66,636)
Reconciliation
Depreciation and amortization expense			(4,907)			(3,630)		(7,863)			(8,157)
Share-based compensation expense			(5,016)			(5,084)		(10,106)			(9,494)
Fair value (loss) / gain - contingent consideration			(1,256)			(2,254)		82			(3,470)
Fair value loss - Liability related to pre-funded warrants			(15,970)			—		(12,201)			—
Foreign currency (losses) / gains, net			(1,730)			18,638		(4,024)			25,810
Interest income			5,051			3,524		10,280			7,651
Interest expense - Royalty Financing Agreement			(12,963)			(13,770)		(25,584)			(27,079)
Interest expense - Hercules loan facility			(1,403)			(1,821)		(2,813)			(3,621)
Other reconciling items			(5,387)			(571)		(5,188)			4,561
Consolidated loss before income tax expense		$	(79,218)		$	(37,294)	$	(132,265)		$	(80,435)

(1)

(2)

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

+ Details

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2026	Jul. 24, 2026
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2026
Document Transition Report	false
Entity File Number	001-36294
Entity Registrant Name	uniQure N.V.
Entity Incorporation, State or Country Code	P7
Entity Tax Identification Number	00-0000000
Entity Address, Address Line One	Paasheuvelweg 25
Entity Address, Postal Zip Code	1105 BP
Entity Address, City or Town	Amsterdam
Entity Address, Country	NL
Country Region	31
City Area Code	20
Local Phone Number	240-6000
Title of 12(b) Security	Ordinary Shares, par value €0.05
Trading Symbol	QURE
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		69,366,412
Entity Central Index Key	0001590560
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2026
Document Fiscal Period Focus	Q2
Amendment Flag	false

Other investments and concentration of credit risk -Schedule of other investments (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Other investments and concentration of credit risk
Carrying amount of equity investments	$ 15,143	$ 15,615
Convertible note receivable	15,124	14,622
Total	$ 30,267	$ 30,237

- Definition

Fair value of investment other than investment in equity security, investment in debt security and equity method investment. Includes, but is not limited to, investment in certain entities that calculate net asset value per share. Example includes, but is not limited to, investment in hedge fund, venture capital fund, private equity fund, and real estate partnership or fund.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-11

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 103
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-103

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 54B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482134/820-10-35-54B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

+ Details

Basic and diluted loss per share

6 Months Ended

Jun. 30, 2026

Basic and diluted loss per share

Basic and diluted loss per share

13Basic and diluted loss per share

Diluted loss per ordinary share is calculated by adjusting the weighted average number of ordinary shares outstanding, assuming conversion of all potentially dilutive ordinary shares. As the Company incurred a loss in the three and six months ended June 30, 2026, all potentially dilutive ordinary shares would have an antidilutive effect, if converted, and thus have been excluded from the computation of diluted loss per share for the three and six months ended June 30, 2026. The ordinary shares are presented without giving effect to the application of the treasury method or exercise prices that would be above the share price as of June 30, 2026 and June 30, 2025, respectively.

The potentially dilutive ordinary shares are summarized below:


	Three months ended June 30,						Six months ended June 30,
	2026			2025			2026			2025
Anti-dilutive ordinary share equivalents
Stock options under 2014 Plans	$	4,962,265		$	5,321,862		$	4,962,265		$	5,321,862
Non-vested RSUs and PSUs		2,536,549			2,442,969			2,536,549			2,442,969
Pre-Funded Warrants		526,316			—			526,316			—
ESPP		13,939			—			13,939			—
Total anti-dilutive ordinary share equivalents		8,039,069			7,764,831			8,039,069			7,764,831

Income taxes (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
Income taxes (Details) - USD ($) $ in Millions	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income taxes
Deferred tax expense	$ 1.8	$ 0.4	$ 2.3	$ 0.9
Effective income tax rate	(2.30%)	(1.10%)	(1.80%)	(1.10%)
Enacted tax rate			25.80%

Insider Trading Arrangements

3 Months Ended

Jun. 30, 2026

Trading Arrangements, by Individual

Material Terms of Trading Arrangement

Adoption of 10b5-1 Trading Plans by Our Officers and Directors

During the three months ended June 30, 2026, the following adopted a “Rule 10b5-1 trading arrangement” (as defined in Item 408(a) of Regulation S-K) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and our policies on insider trading:


Name & Title	Date Adopted⁽¹⁾	Aggregate Number of Ordinary Shares to be Purchased or Sold Pursuant to Trading Arrangement	Expiration Date⁽²⁾
David Meek, Non-executive Director	May 26, 2026	25,860	December 18, 2026

⁽¹⁾ Date of adoption of this Rule 10b5-1 trading arrangement is in accordance with applicable SEC rules and regulations. The first trade pursuant to this Rule 10b5-1 trading arrangement will be, in accordance with applicable SEC rules and regulations, on a date after the date of adoption of the Rule 10b5-1 trading arrangement, to the extent triggered under its terms.

⁽²⁾The Rule 10b5-1 trading arrangement is scheduled to expire on the date listed in the table, subject to earlier termination upon the sale of all shares subject to the Rule 10b5-1 trading arrangement, or as otherwise provided in the Rule 10b5-1 trading arrangement.

Other than those disclosed above, none of our directors or officers adopted, modified, or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” in each case as defined in Item 408 of Regulation S-K, during the three months ended June 30, 2026.

Non-Rule 10b5-1 Arrangement Adopted

false

Non-Rule 10b5-1 Arrangement Terminated

false

Non-Rule 10b5-1 Arr Modified Flag

false

David Meek

Trading Arrangements, by Individual

Name

David Meek

Title

Non-executive Director

Rule 10b5-1 Arrangement Adopted

true

Adoption Date

May 26, 2026

Expiration Date

December 18, 2026

Aggregate Available

25,860

Royalty Financing Agreement - Interest expenses under royalty financing (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income taxes paid
Interest expense for the period			$ 17,384	$ 20,626
Royalty Financing Agreement
Income taxes paid
Interest expense for the period	$ 13,000	$ 13,800	$ 25,584	$ 27,100
Royalty Financing Agreement \| Minimum
Income taxes paid
Effective interest rate (as a percent)	10.00%	12.00%	10.00%	12.00%
Royalty Financing Agreement \| Maximum
Income taxes paid
Effective interest rate (as a percent)	11.50%	13.50%	11.50%	13.50%

Share-based compensation - Option activity and weighted-average assumptions (Details) - 2014 Plan - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
Weighted average exercise price
Total weighted average grant date fair value of options issued during the period (in $ millions)			$ 6.4
Share options
Share-based compensation
Vesting period (in years)			4 years
Number of ordinary shares
Outstanding at beginning of the period (in shares)			4,531,991
Granted (in shares)			869,760
Forfeited (in shares)			(12,451)
Expired (in shares)			(16,186)
Exercised (in shares)			(410,849)
Outstanding at end of the period (in shares)	4,962,265		4,962,265		4,531,991
Thereof, fully vested and exercisable at end of period (in shares)	2,769,675		2,769,675
Outstanding and expected to vest after at end of period (in shares)	2,192,590		2,192,590		1,999,315
Weighted average exercise price
Outstanding at beginning of the period (in dollars per share)			$ 17.04
Granted (in dollars per share)			11.48
Forfeited (in dollars per share)			9.58
Expired (in dollars per share)			37.84
Exercised (in dollars per share)			16.6
Outstanding at end of period (in dollars per share)	$ 16.05		16.05		$ 17.04
Thereof, fully vested and exercisable at end of period (in dollars per share)	$ 19.77		19.77
Outstanding and expected to vest after at end of the period (in dollars per share)			$ 11.35		$ 11.81
Weighted-average assumptions used to estimate fair value of share options granted during year
Expected volatility (as a percent)	95.00%	80.00%	95.00%
Expected volatility, minimum(as a percent)				70.00%
Expected volatility, maximum(as a percent)				80.00%
Expected terms (in years)	10 years	10 years	10 years	10 years
Risk free interest rate (as a percent)	4.68%	4.64%
Risk free interest rate, minimum (as a percent)			4.21%	4.36%
Risk free interest rate, maximum (as a percent)			4.68%	4.64%
Expected dividend yield (as a percent)	0.00%	0.00%	0.00%	0.00%
Non-Executive Directors \| Share options
Share-based compensation
Vesting period (in years)			1 year
One year from grant date \| Share options
Share-based compensation
Vesting period (in years)			1 year
Vesting percentage per year			25.00%

Commitments and contingencies

6 Months Ended

Jun. 30, 2026

Commitments and contingencies

Commitments and contingencies

14Commitments and contingencies

In the course of its business, the Company enters as a licensee into contracts with other parties regarding the development and marketing of its pipeline products. Among other payment obligations, the Company is obligated to pay royalties to the licensors based on future sales levels and milestone payments whenever specified development, regulatory and commercial milestones are met. As both future sales levels and the timing and achievement of milestones are uncertain, the financial effect of these agreements cannot be reliably estimated. The Company also has obligations to make future payments that become due and payable upon the collection of milestone payments from CSL Behring. The achievement and timing of these milestones are not fixed or determinable.

Legal Proceedings

On February 10, 2026, a class action complaint captioned Christopher Scocco v. uniQure N.V., et al., Case No. 1:26-cv-01124, was filed against the Company, certain of its executive officers and another party (collectively, “Defendants”) in the United States District Court for the Southern District of New York. The complaint purported to assert claims pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Rule 10b-5 promulgated thereunder, on behalf of a putative class of investors who purchased or otherwise acquired the Company’s ordinary shares between September 24, 2025 and October 31, 2025 (the “putative Class Period”). The plaintiff sought to recover damages allegedly caused by purported false and misleading statements and omissions with respect to the Company’s Phase I/II study of AMT-130 and the timing of the potential Biologics License Application filing for AMT-130.

On April 13, 2026, the court appointed the Oklahoma Firefighters Pension and Retirement System as lead plaintiff (the “Lead Plaintiff”).

On July 15, 2026, the Lead Plaintiff filed an amended complaint. Like the earlier-filed complaint, the amended complaint purports to assert claims pursuant to Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5, on behalf of a putative class of investors who purchased or otherwise acquired the Company’s ordinary shares during the putative Class Period. Lead Plaintiff seeks unspecified damages allegedly caused by purported false and misleading statements and omissions with respect to the import and viability of data from the Company’s Phase I/II study of AMT-130 and available pathways to regulatory approval. Defendants’ motion to dismiss the amended complaint is currently due September 14, 2026. Management intends to vigorously defend against the claims in this action.

At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company has not recorded any liability for any portion of this matter because the Company believes that liability is not probable and reasonably estimable at this time.

Other investments and concentration of credit risk (Tables)

6 Months Ended

Jun. 30, 2026

Other investments and concentration of credit risk

Schedule of other investments


		June 30,			December 31,
		2026			2025

		(in thousands)
Carrying amount of equity investments		$	15,143		$	15,615
Convertible note receivable			15,124			14,622
Total		$	30,267		$	30,237

Long-term debt

6 Months Ended

Jun. 30, 2026

Long-term debt

Long-term debt

6Long-term debt

The total principal outstanding as of June 30, 2026 under the Company's amended venture debt loan facility with Hercules Capital, Inc. (the “2025 Amended Facility”) was $50.0 million. The amortized cost, including interest due presented as part of Accrued expenses and other current liabilities, was $50.5 million as of June 30, 2026, compared to $50.1 million as of December 31, 2025, and is recorded net of discount and debt issuance costs.

The foreign currency loss on the loan facility in the three and six months ended June 30, 2026 was $0.5 million and $1.6 million, respectively, compared to a foreign currency gain of $4.3 million and $6.4 million, respectively, during the same periods in 2025. Interest expense during the three and six months ended June 30, 2026 was $1.4 million and $2.8 million, respectively, compared to $1.8 million and $3.6 million, respectively, during the same periods in 2025.

During the six months ended June 30, 2026, there were no material changes to the terms, available borrowing tranches, covenants, or collateral arrangements of the 2025 Amended Facility as described in Note 11, “Long-term debt” to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. As of June 30, 2026, the Company was in compliance with all applicable covenants under the facility.

In July 2026, subsequent to the balance sheet date, the Company entered into an amendment to its loan facility with Hercules Capital, Inc. (as amended, the “2026 Amended Facility”). The amendment extended the period during which the Company may draw the $100.0 million term loan tranche from June 15, 2027 to September 30, 2027. Except as provided for in the amendment, the terms of borrowing under the 2026 Amended Facility remained unchanged.

Subsequent events (Details) $ in Millions	Jul. 31, 2026 USD ($)
Subsequent event \| Tranche Based on Approval of AMT-130 \| 2026 Amended Facility
Subsequent events
Maximum borrowing capacity	$ 100.0

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets
Cash and cash equivalents	$ 413,027	$ 80,240
Current investment securities	397,308	542,301
Accounts receivable	5,778	5,863
Prepaid expenses	10,245	20,506
Other current assets and receivables	7,911	7,076
Total current assets	834,269	655,986
Non-current assets
Property, plant and equipment, net	11,376	13,800
Other investments	30,267	30,237
Operating lease right-of-use assets	11,606	12,525
Intangible assets, net	62,101	72,790
Goodwill	24,587	25,355
Deferred tax assets, net	6,362	8,654
Other non-current assets	4,535	5,561
Total non-current assets	150,834	168,922
Total assets	985,103	824,908
Current liabilities
Accounts payable	4,979	5,170
Accrued expenses and other current liabilities	51,133	41,292
Liability related to pre-funded warrants	24,242	12,595
Current portion of operating lease liabilities	2,991	3,862
Total current liabilities	83,345	62,919
Non-current liabilities
Long-term debt	50,147	49,699
Liability from royalty financing agreement	489,333	473,199
Operating lease liabilities, net of current portion	9,696	9,832
Contingent consideration	18,113	18,736
Deferred tax liability, net	7,726	7,967
Other non-current liabilities, net of current portion	2,693	3,655
Total non-current liabilities	577,708	563,088
Total liabilities	661,053	626,007
Commitments and contingencies
Shareholders' equity
Ordinary shares, €0.05 par value: 100,000,000 shares authorized at June 30, 2026, and 80,000,000 at December 31, 2025, and 69,334,839 and 62,336,717 shares issued and outstanding at June 30, 2026, and December 31, 2025, respectively.	4,086	3,688
Additional paid-in-capital	1,841,745	1,582,371
Accumulated other comprehensive loss	(58,251)	(58,222)
Accumulated deficit	(1,463,530)	(1,328,936)
Total shareholders' equity	324,050	198,901
Total liabilities and shareholders' equity	$ 985,103	$ 824,908

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
License revenues	$ 5,841	$ 5,262	$ 9,403	$ 6,829
Total revenues	5,841	5,262	9,403	6,829
Operating expenses:
Cost of license revenues	(350)	(656)	(569)	(853)
Research and development expenses	(33,964)	(35,383)	(63,140)	(71,523)
Selling, general and administrative expenses	(17,367)	(13,500)	(37,435)	(24,408)
Total operating expenses	(51,681)	(49,539)	(101,144)	(96,784)
Other income	1,598	2,597	3,230	10,903
Other expense	(7,961)	(2,185)	(9,412)	(4,144)
Loss from operations	(52,203)	(43,865)	(97,923)	(83,196)
Interest income	5,051	3,524	10,280	7,651
Interest expense	(14,366)	(15,591)	(28,397)	(30,700)
Foreign currency (losses) / gains, net	(1,730)	18,638	(4,024)	25,810
Other non-operating (losses), net	(15,970)		(12,201)
Loss before income tax expense	(79,218)	(37,294)	(132,265)	(80,435)
Income tax expense	(1,841)	(425)	(2,329)	(921)
Net loss	(81,059)	(37,719)	(134,594)	(81,356)
Other comprehensive loss:
Foreign currency translation gains / (losses), net	1,634	(5,098)	(29)	(6,103)
Total comprehensive loss	$ (79,425)	$ (42,817)	$ (134,623)	$ (87,459)
Loss per ordinary share - basic
Basic net loss per ordinary share	$ (1.22)	$ (0.69)	$ (2.09)	$ (1.49)
Loss per ordinary share - diluted
Diluted net loss per ordinary share	$ (1.22)	$ (0.69)	$ (2.09)	$ (1.49)
Weighted average shares - basic	66,243,879	54,807,967	64,503,035	54,540,423
Weighted average shares - diluted	66,243,879	54,807,967	64,503,035	54,540,423

Share-based compensation

6 Months Ended

Jun. 30, 2026

Share-based compensation

Share-based compensation

9Share-based compensation

The Company’s share-based compensation plans include the amended and restated 2014 Share Incentive Plan (as amended, the “2014 Plan”) and inducement grants under Rule 5653(c)(4) of the Nasdaq Global Select Market with terms similar to the 2014 Plan (together the “2014 Plans”). At the annual general meeting of shareholders in June 2026, the Company’s shareholders authorized an additional 350,000 ordinary shares for issuance under the 2014 Plan. As of June 30, 2026, a total of 2,815,628 ordinary shares remain available for issuance under the 2014 Plan.

In June 2018, the Company’s shareholders adopted and approved the uniQure N.V. Employee Stock Purchase Plan (as amended, the “ESPP”) allowing the Company to issue up to 150,000 ordinary shares. The ESPP is intended to qualify under Section 423 of the Internal Revenue Code of 1986, as amended. Under the ESPP, employees are eligible to purchase ordinary shares through payroll deductions, subject to any plan limitations. The purchase price of the ordinary shares on each purchase date is equal to the lower of: (i) 85% of the closing market price on the offering date or (ii) 85% of the closing market price on the purchase date.

2014 Plans and ESPP

Share-based compensation expense recognized by classification included in the Unaudited Consolidated Statements of Operations and Comprehensive Loss in relation to the 2014 Plans and the ESPP for the periods indicated below was as follows:

Three months ended June 30,

Six months ended June 30,

 

2026

 

2025

 

2026

 

2025

(in thousands)

Research and development expenses

1,888

2,758

3,865

5,221

Selling, general and administrative expenses

3,128

2,326

6,241

4,273

Total

5,016

5,084

10,106

9,494

Share-based compensation expense recognized by award type for the 2014 Plans as well as the ESPP was as follows:


		Three months ended June 30,						Six months ended June 30,
		2026			2025			2026			2025

		(in thousands)						(in thousands)
Award type/ESPP
Share options		$	1,861		$	1,662		$	3,668		$	3,299
Restricted share units			3,255			2,547			6,461			4,760
Performance share units			(108)			875			(46)			1,435
ESPP			8			—			23			—
Total		$	5,016		$	5,084		$	10,106		$	9,494

As of June 30, 2026, the unrecognized share-based compensation expense related to unvested awards under the 2014 Plans was:


	Unrecognized		Weighted average
	share-based		remaining
	compensation		period for
	expense		recognition
	(in thousands)		(in years)
Award type
Share options	$	14,464	2.57
Restricted share units		25,886	2.17
Performance share units		427	0.87
Total	$	40,776	2.30

The Company satisfies the exercise of share options and vesting of Restricted Share Units (“RSUs”) and Performance Share Units (“PSUs”) through newly issued ordinary shares.

Share options

Share options are priced on the date of grant and, except for certain grants made to non-executive directors, vest over a period of four years. The first 25% of each grant vests one year after the initial grant date and the remainder vests in equal quarterly installments over years two, three and four. Certain grants to non-executive directors vest in full after one year. Any options that vest must be exercised by the tenth anniversary of the initial grant date.

The following table summarizes option activity under the 2014 Plans for the six months ended June 30, 2026:


	Options
	Number of ordinary shares			Weighted average exercise price

Outstanding at December 31, 2025	4,531,991			17.04
Granted	869,760		$	11.48
Forfeited	(12,451)		$	9.58
Expired	(16,186)		$	37.84
Exercised	(410,849)		$	16.60
Outstanding at June 30, 2026	4,962,265		$	16.05
Thereof, fully vested, and exercisable on June 30, 2026	2,769,675		$	19.77
Thereof, outstanding and expected to vest after June 30, 2026	2,192,590		$	11.35
Outstanding and expected to vest after December 31, 2025	1,999,315		$	11.81


Total weighted average grant date fair value of options issued during the period (in $ millions)				$	6.4

The fair value of each option issued is estimated at the respective grant date using the Hull & White option pricing model with the following weighted-average assumptions:


		Three months ended June 30,				Six months ended June 30,
		2026		2025		2026		2025
Assumptions
Expected volatility		95%		80%		95%		70% - 80%
Expected terms		10 years		10 years		10 years		10 years
Risk-free interest rate		4.68%		4.64%		4.21% - 4.68%		4.36% - 4.64%
Expected dividend yield		0.0%		0.0%		0.0%		0.0%

RSUs

The following table summarizes the RSU activity for the six months ended June 30, 2026:


	RSUs
		Weighted average
	Number of	grant-date fair
	ordinary shares	value
Non-vested at December 31, 2025	2,395,420	$	12.15
Granted	1,112,250	$	12.36
Vested	(886,521)	$	12.29
Forfeited	(113,350)	$	16.22
Non-vested at June 30, 2026	2,507,799	$	12.01

Total weighted average grant date fair value of RSUs granted during the period (in $ millions)		$	13.8

RSUs are measured at grant date based on the market price of the Company’s ordinary shares and, except for certain grants made to non-executive directors, vest over a three-year period. RSUs granted to non-executive directors vest one year after the date of grant.

PSUs

The Company granted PSUs to certain employees in 2024 and 2026, that, with respect to the 2024 PSUs, would have been earned upon the Board of Directors’ assessment of the level of achievement of an agreed upon performance target, and, with respect to the 2026 PSUs, will be earned upon Company management’s assessment of the level of achievement of agreed upon performance targets, subject, in each case, to the grantee’s continued employment. The fair value of PSUs granted in 2024 and 2026 was determined on the grant date by reference to the market price of the Company’s ordinary shares.

The Company recognizes the compensation cost related to these grants to the extent it considers achievement of the milestones to be probable. As of June 30, 2026, certain 2026 PSUs were assessed as probable of achieving the requisite performance condition.

As of June 30, 2026, the Company determined that the performance target for the outstanding 2024 PSUs were not met within the contractually defined performance period and were consequently forfeited.

The following table summarizes the PSU activity for the six months ended June 30, 2026:


	PSUs
		Weighted average
	Number of	grant-date fair
	ordinary shares	value
Non-vested at December 31, 2025	22,500	$	15.40
Granted	28,750	$	22.40
Vested	—	$	—
Forfeited	(22,500)	$	15.40
Non-vested at June 30, 2026	28,750	$	22.40

ESPP

During the six months ended June 30, 2026, 13,939 ordinary shares were issued under the ESPP compared to nil ordinary shares issued during the same period in 2025. As of June 30, 2026, 72,773 ordinary shares remain available for issuance under the ESPP compared to a total of 86,712 ordinary shares as of June 30, 2025.

Royalty Financing Agreement

6 Months Ended

Jun. 30, 2026

Royalty Financing Agreement

Royalty Financing Agreement

7Royalty Financing Agreement

During the six months ended June 30, 2026, there were no material changes to the terms of the royalty purchase agreement entered into in May 2023 (the “Royalty Financing Agreement”) with HemB SPV, L.P. (the “Purchaser”), as described in Note 12, “Royalty Financing Agreement” within the consolidated financial statements included in the Company’s Annual Report for the year ended December 31, 2025.

The following table presents the changes in the liability from the Royalty Financing Agreement for the period from December 31, 2025 to June 30, 2026:


	Amount of liability
	(in thousands)
Balance as of December 31, 2025 (includes $5.5 million presented as "Accrued expenses and other current liabilities")	$	478,722
Royalty payments to the Purchaser		(9,195)
Interest expense for the period		25,584
Balance as of June 30, 2026 (includes $5.8 million presented as "Accrued expenses and other current liabilities")	$	495,111

The Company records the debt at amortized cost using the effective interest method based on projected cash flows. As of June 30, 2026, the effective interest rate is expected to be within a range of 10.0% to 11.5% per annum (June 30, 2025: 12.0% to 13.5%). Interest expense recorded in connection with the Royalty Financing Agreement was $13.0 million and $13.8 million for the three months ended June 30, 2026 and 2025, respectively, and $25.6 million and $27.1 million for the six months ended June 30, 2026 and 2025, respectively.

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Pay vs Performance Disclosure
Net Income (Loss)	$ (81,059)	$ (37,719)	$ (134,594)	$ (81,356)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (24)(d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Fair value measurement - Changes in fair value of pre funded warrants (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2026 USD ($)
Fair value measurement.
Beginning balance	$ 12,595
Changes in fair value of liability related to pre-funded warrants	12,201
Currency translation effects	(554)
Ending balance	$ 24,242

Fair value measurement - Assets and liabilities measured on a recurring basis (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025	Jun. 30, 2025
Assets:
Restricted cash	$ 1,534		$ 1,494
Liabilities:
Liability related to pre-funded warrants	24,242	$ 12,595
Recurring Fair Value Measurements
Assets:
Cash and cash equivalents	413,027	80,240
Restricted cash	1,534	1,561
Total assets	414,561	81,801
Liabilities:
Liability related to pre-funded warrants	24,242	12,595
Contingent consideration	18,113	18,736
Consideration for post-acquisition services	617	638
Total liabilities	42,972	31,969
Recurring Fair Value Measurements \| Quoted prices in active markets (Level 1)
Assets:
Cash and cash equivalents	413,027	80,240
Restricted cash	1,534	1,561
Total assets	414,561	81,801
Recurring Fair Value Measurements \| Significant other observable inputs (Level 2)
Liabilities:
Liability related to pre-funded warrants	24,242	12,595
Total liabilities	24,242	12,595
Recurring Fair Value Measurements \| Significant unobservable inputs (Level 3)
Liabilities:
Contingent consideration	18,113	18,736
Consideration for post-acquisition services	617	638
Total liabilities	$ 18,730	$ 19,374

Accrued expenses and other current liabilities

6 Months Ended

Jun. 30, 2026

Accrued expenses and other current liabilities

Accrued expenses and other current liabilities

5	Accrued expenses and other current liabilities

Accrued expenses and other current liabilities include the following items:


		June 30,		December 31,
		2026		2025

		(in thousands)
Accruals for goods received from and services provided by vendors, not yet billed		$	24,684	$	20,490
Personnel-related accruals and liabilities (As of June 30, 2026, $7.2 million (December 31, 2025: $0.0 million) related to cash proceeds from employees' stock option exercises)			16,654		9,941
Liability owed to the Purchaser pursuant to the Royalty Financing Agreement (refer to Note 7, "Royalty Financing Agreement")			5,778		5,523
Current portion of firm purchase commitment liability (including Genezen CSA termination payment)			3,808		5,102
Other current liabilities			209		236
Total		$	51,133	$	41,292

In April 2026, the Company entered into an agreement to terminate the commercial supply agreement (the “Genezen CSA”) with Genezen MA, Inc. (together with Genezen Holdings Inc., “Genezen”). Pursuant to the termination agreement, our obligation to supply HEMGENIX^® and any minimum purchase commitments under the Genezen CSA terminate once contractually specified batches have been supplied. In connection with the termination, the Company wrote down the remaining carrying value of the intangible asset for the favorable supply terms under the Genezen CSA. The net effect of these items was recorded in Other expense, and did not have a material impact on the Company’s results of operations for the three and six months ended June 30, 2026.

General business information

6 Months Ended

Jun. 30, 2026

General business information

General business information

1General business information

uniQure N.V. (the “Company”) was incorporated on January 9, 2012, as a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) under the laws of the Netherlands. The Company is a leader in the field of gene therapy and seeks to deliver to patients suffering from rare and other devastating diseases single treatments with potentially curative results. The Company’s business was founded in 1998 and was initially operated through its predecessor company, Amsterdam Molecular Therapeutics Holding N.V. (“AMT”). In 2012, AMT undertook a corporate reorganization, pursuant to which uniQure B.V. acquired the entire business and assets of AMT and completed a share-for-share exchange with the shareholders of AMT. Effective February 10, 2014, in connection with its initial public offering, the Company converted into a public company with limited liability (naamloze vennootschap) and changed its legal name from uniQure B.V. to uniQure N.V.

The Company is registered in the trade register of the Dutch Chamber of Commerce (Kamer van Koophandel) in Amsterdam, the Netherlands under number 54385229. The Company’s headquarters are in Amsterdam, the Netherlands, its registered office is located at Paasheuvelweg 25, Amsterdam 1105 BP, the Netherlands and its telephone number is +31 20 240 6000.

The Company’s ordinary shares are listed on the Nasdaq Global Select Market and trade under the symbol “QURE”.

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities
Net loss	$ (134,594)	$ (81,356)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	7,863	8,157
Amortization of discount on investment securities	(7,907)	(4,163)
Share-based compensation expense	10,106	9,494
Royalty financing agreement interest expense, net of interest paid	17,384	20,626
Deferred tax expense	2,329	921
Changes in fair value of contingent consideration	(82)	3,470
Changes in fair value of liability related to pre-funded warrants	12,201
Unrealized foreign exchange losses / (gains), net	8,329	(25,163)
Other items, net	(2,426)	(3,651)
Changes in operating assets and liabilities:
Accounts receivable, prepaid expenses, and other current assets and receivables	8,846	(6,761)
Accounts payable	68	(2,297)
Accrued expenses, other liabilities, and operating leases	11,064	(3,272)
Net cash used in operating activities	(66,819)	(83,995)
Cash flows from investing activities
Proceeds on maturity of debt securities	384,981	213,763
Investments in debt securities	(232,550)	(120,205)
Purchases of property, plant, and equipment	(612)	(386)
Net cash generated from investing activities	151,819	93,172
Cash flows from financing activities
Proceeds from follow-on public offering of ordinary shares, net of issuance costs	242,681	80,511
Proceeds from issuance of ordinary shares related to employee stock options and purchase plans	6,985	203
Net cash generated from financing activities	249,666	80,714
Currency effect on cash, cash equivalents and restricted cash	(1,906)	5,052
Net increase in cash, cash equivalents and restricted cash	332,760	94,943
Cash, cash equivalents and restricted cash at the beginning of period	81,801	160,329
Cash, cash equivalents and restricted cash at the end of period	414,561	255,272
Cash and cash equivalents	413,027	253,778
Restricted cash related to leasehold and other deposits	1,534	1,494
Total cash, cash equivalents and restricted cash	414,561	255,272
Supplemental cash flow disclosures:
Cash paid for interest	$ (11,494)	$ (9,652)

CONSOLIDATED BALANCE SHEETS (Parenthetical) - € / shares	Jun. 30, 2026	Dec. 31, 2025
CONSOLIDATED BALANCE SHEETS
Ordinary shares, par value (in euros per share)	€ 0.05	€ 0.05
Ordinary shares, authorized	100,000,000	80,000,000
Ordinary shares, issued	69,334,839	62,336,717
Ordinary shares, outstanding	69,334,839	62,336,717

Royalty Financing Agreement (Tables)

6 Months Ended

Jun. 30, 2026

Royalty Financing Agreement

Schedule of movement in the liability related to royalty financing agreement


	Amount of liability
	(in thousands)
Balance as of December 31, 2025 (includes $5.5 million presented as "Accrued expenses and other current liabilities")	$	478,722
Royalty payments to the Purchaser		(9,195)
Interest expense for the period		25,584
Balance as of June 30, 2026 (includes $5.8 million presented as "Accrued expenses and other current liabilities")	$	495,111

Fair value measurement (Tables)

6 Months Ended

Jun. 30, 2026

Fair value measurement.

Schedule of assets and liabilities measured at fair value on recurring basis


		Quoted prices in active markets (Level 1)			Significant other observable inputs (Level 2)			Significant unobservable inputs (Level 3)			Total			Classification in Unaudited Consolidated Balance Sheets

			(in thousands)
Balance at December 31, 2025
Assets:
Cash and cash equivalents		$	80,240		$	—		$	—		$	80,240		Cash and cash equivalents
Restricted cash			1,561			—			—			1,561		Other non-current assets
Total assets		$	81,801		$	—		$	—		$	81,801
Liabilities:
Liability related to pre-funded warrants			—			12,595			—			12,595		Liability related to pre-funded warrants
Contingent consideration			—			—			18,736			18,736		Contingent consideration
Consideration for post-acquisition services			—			—			638			638		Other non-current liabilities
Total liabilities		$	—		$	12,595		$	19,374		$	31,969
Balance at June 30, 2026
Assets:
Cash and cash equivalents		$	413,027		$	—		$	—		$	413,027		Cash and cash equivalents
Restricted cash			1,534			—			—			1,534		Other non-current assets
Total assets		$	414,561		$	—		$	—		$	414,561
Liabilities:
Liability related to pre-funded warrants			—			24,242			—			24,242		Liability related to pre-funded warrants
Contingent consideration			—			—			18,113			18,113		Contingent consideration
Consideration for post-acquisition services			—			—			617			617		Other non-current liabilities
Total liabilities		$	—		$	24,242		$	18,730		$	42,972

Schedule of changes in fair value of contingent consideration


	Amount of
	contingent
	consideration
	(in thousands)
Balance at December 31, 2025	$	18,736
Unrealized change in fair value (presented within Research and development expenses)		(82)
Currency translation effects		(541)
Balance at June 30, 2026	$	18,113

Schedule of changes in fair value of pre funded warrants


	Liability related
	to pre-funded
	warrants
	(in thousands)
Balance at December 31, 2025	$	12,595
Unrealized increase in fair value (presented within Other non-operating (losses), net)		12,201
Currency translation effects		(554)
Balance at June 30, 2026	$	24,242

Income taxes

6 Months Ended

Jun. 30, 2026

Income taxes

Income taxes

12	Income taxes

The Company recorded a deferred tax expense of $1.8 million and $2.3 million related to its U.S. operations during the three and six months ended June 30, 2026 ($0.4 million and $0.9 million for the three and six months ended June 30, 2025).

The effective income tax rate of 2.3% and 1.8% during the three and six months ended June 30, 2026 (three and six months ended June 30, 2025: 1.1% and 1.1%, respectively) is substantially lower than the enacted rate of 25.8% in the Netherlands as the Company recorded a valuation allowance against its net deferred tax assets in the Netherlands and a partial valuation allowance against its net deferred tax assets in France, among various other items which impacted the effective rate.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477617/942-740-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478822/944-740-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

Accrued expenses and other current liabilities (Tables)

6 Months Ended

Jun. 30, 2026

Accrued expenses and other current liabilities

Schedule of accrued expenses and other current liabilities


		June 30,		December 31,
		2026		2025

		(in thousands)
Accruals for goods received from and services provided by vendors, not yet billed		$	24,684	$	20,490
Personnel-related accruals and liabilities (As of June 30, 2026, $7.2 million (December 31, 2025: $0.0 million) related to cash proceeds from employees' stock option exercises)			16,654		9,941
Liability owed to the Purchaser pursuant to the Royalty Financing Agreement (refer to Note 7, "Royalty Financing Agreement")			5,778		5,523
Current portion of firm purchase commitment liability (including Genezen CSA termination payment)			3,808		5,102
Other current liabilities			209		236
Total		$	51,133	$	41,292

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY / (DEFICIT) - USD ($) $ in Thousands	Ordinary shares	Additional paid-in capital	Accumulated other comprehensive loss gain / (loss)	Accumulated deficit	Total
Beginning balance at Dec. 31, 2024	$ 2,945	$ 1,173,068	$ (52,800)	$ (1,129,965)	$ (6,752)
Beginning balance (in shares) at Dec. 31, 2024	48,988,087
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY / (DEFICIT)
Loss for the period				(81,356)	(81,356)
Other comprehensive gain (loss), net			(6,103)		(6,103)
Follow-on public offering	$ 261	80,250			80,511
Follow-on public offering (in shares)	5,073,529
Exercises of share options	$ 1	202			203
Exercises of share options (in shares)	21,240
Restricted and performance share units distributed during the period	$ 43	(43)
Restricted and performance share units distributed during the period (in shares)	782,817
Share-based compensation expense		9,494			9,494
Ending balance at Jun. 30, 2025	$ 3,250	1,262,971	(58,903)	(1,211,321)	(4,003)
Ending balance (in shares) at Jun. 30, 2025	54,865,673
Beginning balance at Mar. 31, 2025	$ 3,240	1,257,853	(53,805)	(1,173,602)	33,686
Beginning balance (in shares) at Mar. 31, 2025	54,698,479
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY / (DEFICIT)
Loss for the period				(37,719)	(37,719)
Other comprehensive gain (loss), net			(5,098)		(5,098)
Exercises of share options		44			44
Exercises of share options (in shares)	5,312
Restricted and performance share units distributed during the period	$ 10	(10)
Restricted and performance share units distributed during the period (in shares)	161,882
Share-based compensation expense		5,084			5,084
Ending balance at Jun. 30, 2025	$ 3,250	1,262,971	(58,903)	(1,211,321)	(4,003)
Ending balance (in shares) at Jun. 30, 2025	54,865,673
Beginning balance at Dec. 31, 2025	$ 3,688	1,582,371	(58,222)	(1,328,936)	$ 198,901
Beginning balance (in shares) at Dec. 31, 2025	62,336,717				62,336,717
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY / (DEFICIT)
Loss for the period				(134,594)	$ (134,594)
Other comprehensive gain (loss), net			(29)		(29)
Follow-on public offering	$ 323	242,359			242,681
Follow-on public offering (in shares)	5,686,813
Exercises of share options	$ 24	6,796			6,820
Exercises of share options (in shares)	410,849
Restricted and performance share units distributed during the period	$ 51	(51)
Restricted and performance share units distributed during the period (in shares)	886,521
Issuance of ordinary shares relating to employee stock purchase plan	$ 1	164			165
Issuance of ordinary shares relating to employee stock purchase plan (in shares)	13,939
Share-based compensation expense		10,106			10,106
Ending balance at Jun. 30, 2026	$ 4,086	1,841,745	(58,251)	(1,463,530)	$ 324,050
Ending balance (in shares) at Jun. 30, 2026	69,334,839				69,334,839
Beginning balance at Mar. 31, 2026	$ 3,728	1,587,971	(59,885)	(1,382,471)	$ 149,343
Beginning balance (in shares) at Mar. 31, 2026	63,033,249
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY / (DEFICIT)
Loss for the period				(81,059)	(81,059)
Other comprehensive gain (loss), net			1,634		1,634
Follow-on public offering	$ 323	242,359			242,681
Follow-on public offering (in shares)	5,686,813
Exercises of share options	$ 23	6,412			6,435
Exercises of share options (in shares)	385,541
Restricted and performance share units distributed during the period	$ 13	(13)
Restricted and performance share units distributed during the period (in shares)	229,236
Share-based compensation expense		5,016			5,016
Ending balance at Jun. 30, 2026	$ 4,086	$ 1,841,745	$ (58,251)	$ (1,463,530)	$ 324,050
Ending balance (in shares) at Jun. 30, 2026	69,334,839				69,334,839

Current investment securities (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current investments securities:
Amortized cost	$ 397,308	$ 542,301
Gross unrealized holding gains	30	308
Estimated fair value	397,338	542,609
Expected credit loss	0	0
Government debt securities (held-to-maturity)
Current investments securities:
Amortized cost	397,308	542,301
Gross unrealized holding gains	30	308
Estimated fair value	$ 397,338	$ 542,609

Subsequent events

6 Months Ended

Jun. 30, 2026

Subsequent events

Subsequent events

15Subsequent events